{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Ezetimibe", "query": { "intervention": "Placebo Ezetimibe" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 53, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Ezetimibe&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T14:47:10.226Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07219602", "title": "A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lipidemia", "Type 2 Diabetes (T2DM)", "Metabolic Syndrome (MetS)" ], "interventions": [ { "name": "obicetrapib 10 mg + ezetimibe 10 mg FDC daily", "type": "DRUG" }, { "name": "Obicetrapib 10 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-12-11", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 32, "location_summary": "Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more", "locations": [ { "city": "Sun City West", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07219602" }, { "nct_id": "NCT01644188", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo (for ezetimibe)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 720, "start_date": "2012-08", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644188" }, { "nct_id": "NCT00965055", "title": "Ezetimibe in Patients Hypo-responsive to Statins", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High Cholesterol", "Coronary Artery Disease" ], "interventions": [ { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 2, "start_date": "2009-09", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2019-08-21", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00965055" }, { "nct_id": "NCT01730040", "title": "Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2012-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-31", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 56, "location_summary": "Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730040" }, { "nct_id": "NCT01709513", "title": "Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2012-09-30", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 41, "location_summary": "Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709513" }, { "nct_id": "NCT03051100", "title": "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Bempedoic acid 180mg", "type": "DRUG" }, { "name": "Ezetimibe 10mg", "type": "DRUG" }, { "name": "Atorvastatin 20mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2017-01-19", "completion_date": "2017-07-05", "has_results": true, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 11, "location_summary": "Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more", "locations": [ { "city": "Champaign", "state": "Illinois" }, { "city": "Cary", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Hickory", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03051100" }, { "nct_id": "NCT05763875", "title": "Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Inclisiran", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Matching Placebo for Inclisiran", "type": "DRUG" }, { "name": "Matching Placebo for Ezetimibe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 350, "start_date": "2023-03-15", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "DeLand", "state": "Florida" }, { "city": "Maitland", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05763875" }, { "nct_id": "NCT06005597", "title": "Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemias", "Hypercholesterolemia", "Familial Hypercholesterolemia", "ASCVD", "High Cholesterol" ], "interventions": [ { "name": "Combination Therapy", "type": "COMBINATION_PRODUCT" }, { "name": "Monotherapy obicetrapib", "type": "DRUG" }, { "name": "Monotherapy ezetimibe", "type": "DRUG" }, { "name": "Combination Therapy placebo", "type": "OTHER" }, { "name": "Obicetrapib Placebo", "type": "OTHER" }, { "name": "Ezetimibe Placebo", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG", "OTHER" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2024-03-01", "completion_date": "2024-10-16", "has_results": true, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 45, "location_summary": "Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06005597" }, { "nct_id": "NCT00701727", "title": "Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiant Research", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 31, "start_date": "2008-06", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2011-04-18", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00701727" }, { "nct_id": "NCT00687076", "title": "Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Niaspan", "type": "DRUG" }, { "name": "Statin therapy", "type": "DRUG" }, { "name": "Standard care", "type": "BEHAVIORAL" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Placebo Niaspan", "type": "DRUG" }, { "name": "Placebo Ezetimibe", "type": "DRUG" }, { "name": "Percutaneous transluminal angioplasty (PTA)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 102, "start_date": "2004-04", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2020-02-06", "last_synced_at": "2026-09-14T14:47:10.226Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00687076" } ] }